Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics

Gastroenterology

Volumn 130, Issue 6, 2006, Pages 1793-1806

  Ho, Richard H ^a,b   Tirona, Rommel G ^a,b   Leake, Brenda F ^a,b   Glaeser, Hartmut ^a,b   Lee, Wooin ^a,b   Lemke, Christopher J ^a,b   Wang, Yi ^c   Kim, Richard B ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CARRIER PROTEINS AND BINDING PROTEINS; MESSENGER RNA; ORGANIC ANION TRANSPORTER 2; RNA; ROSUVASTATIN; SODIUM DEPENDENT TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER PRESERVATION; MALE; MEDICAL ASSESSMENT; MESSENGER RNA SYNTHESIS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN VARIANT; RAT; RNA ANALYSIS; TISSUE SECTION; TREATMENT RESPONSE;

EID: 33646536542     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.034     Document Type: Article

References (41)

1. American Heart Association. Heart disease and stroke statistics-2005 Update. 1-60 (2005), American Heart Association, Dallas, TX
2. Williams K.J., and Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9 (1998) 471-474
3. Levine G.N., Keaney Jr. J.F., and Vita J.A. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 332 (1995) 512-521
4. Vaughan C.J., Gotto Jr. A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
5. McKenney J.M. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 62 (2005) 1033-1047
6. Martin P.D., Warwick M.J., Dane A.L., Brindley C., and Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25 (2003) 2553-2563
7. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., and Warwick M. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87 (2001) 28B-32B
8. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.P., and Kirchgessner T.G. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274 (1999) 37161-37168
9. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 4 (2003) 9-14
10. Kim R.B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33 Suppl 2 (2003) 1-5
11. Schneck D.W., Birmingham B.K., Zalikowski J.A., Mitchell P.D., Wang Y., Martin P.D., Lasseter K.C., Brown C.D., Windass A.S., and Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75 (2004) 455-463
12. Simonson S.G., Raza A., Martin P.D., Mitchell P.D., Jarcho J.A., Brown C.D., Windass A.S., and Schneck D.W. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76 (2004) 167-177
13. Regazzi M.B., Iacona I., Campana C., Raddato V., Lesi C., Perani G., Gavazzi A., and Vigano M. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25 (1993) 2732-2734
14. Shitara Y., Itoh T., Sato H., Li A.P., and Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304 (2003) 610-616
15. Tirona R.G., Leake B.F., Wolkoff A.W., and Kim R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304 (2003) 223-228
16. Tirona R.G., Leake B.F., Merino G., and Kim R.B. Polymorphisms in OATP-C. identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276 (2001) 35669-35675
17. Ho R.H., Leake B.F., Roberts R.L., Lee W., and Kim R.B. Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 279 (2004) 7213-7222
18. Kim R.B., Leake B., Cvetkovic M., Roden M.M., Nadeau J., Walubo A., and Wilkinson G.R. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther 291 (1999) 1204-1209
19. Singer I.I., Kawka D.W., Kazazis D.M., Alberts A.W., Chen J.S., Huff J.W., and Ness G.C. Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers. Proc Natl Acad Sci U S A 81 (1984) 5556-5560
20. Tan E., Tirona R.G., and Pang K.S. Lack of zonal uptake of estrone sulfate in enriched periportal and perivenous isolated rat hepatocytes. Drug Metab Dispos 27 (1999) 336-341
21. Paulusma C.C., Kothe M.J., Bakker C.T., Bosma P.J., van Bokhoren I., van Marle J., Bolder U., Tytgat G.N., and Oude Elferink R.P. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 31 (2000) 684-693
22. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., and Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68 (2005) 800-807
23. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., and Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61 (2001) 3458-3464
24. Kouzuki H., Suzuki H., Ito K., Ohashi R., and Sugiyama Y. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 286 (1998) 1043-1050
25. Duffy M.C., Blitzer B.L., and Boyer J.L. Direct determination of the driving forces for taurocholate uptake into rat liver plasma membrane vesicles. J Clin Invest 72 (1983) 1470-1481
26. Satlin L.M., Amin V., and Wolkoff A.W. Organic anion transporting polypeptide mediates organic anion/HCO3- exchange. J Biol Chem 272 (1997) 26340-26345
27. Davidson M.H., and Toth P.P. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 47 (2004) 73-104
28. Mwinyi J., Johne A., Bauer S., Roots I., and Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75 (2004) 415-421
29. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Takane H., Irie S., Kusuhara H., Urasaki Y., Urae A., Higuchi S., Otsubo K., and Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes. consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73 (2003) 554-565
30. Niemi M., Schaeffeler E., Lang T., Fromm M.F., Neuvonen M., Kyrklund C., Backman J.T., Kerb R., Schwab M., Neuvonen P.J., Eichelbaum M., and Kivisto K.T. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14 (2004) 429-440
31. Nozawa T., Nakajima M., Tamai I., Noda K., Nezu J., Sai Y., Tsuji A., and Yokoi T. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9). allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302 (2002) 804-813
32. Tachibana-Iimori R., Tabara Y., Kusuhara H., Kohara K., Kawamoto R., Nakura J., Tokunaga K., Kondo I., Sugiyama Y., and Miki T. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19 (2004) 375-380
33. Morimoto K., Ueda S., Seki N., Igawa Y., Kameyama Y., Shimizu A., Oishi T., Hosokawa M., Iesato K., Mori S., Saito Y., and Chiba K. OATP-C (OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients. (abstr). Clin Pharmacol Ther 77 (2005) 21
34. Trauner M., and Boyer J.L. Bile salt transporters. molecular characterization, function, and regulation. Physiol Rev 83 (2003) 633-671
35. Hagenbuch B., and Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch 447 (2004) 566-570
36. Baker T.K., Carfagna M.A., Gao H., Dow E.R., Li Q., Searfoss G.H., and Ryan T.P. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem Res Toxicol 14 (2001) 1218-1231
37. Jigorel E., Le Vee M., Boursier-Neyret C., Bertrand M., and Fardel O. Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metab Dispos 33 (2005) 1418-1422
38. Shitara Y., Li A.P., Kato Y., Lu C., Ito K., Itoh T., and Sugiyama Y. Function of uptake transporters for taurocholate and estradiol 17β-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18 (2003) 33-41
39. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Raza A., and Schneck D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 55 (2003) 94-99
40. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., Low M., Greenson J.K., and Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
41. Garcia P.J. Pleiotropic effects of statins. moving beyond cholesterol control. Curr Atheroscler Rep 7 (2005) 34-39